New hope for cancer patients: drug may stop dangerous weight loss before surgery
NCT ID NCT07391826
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a drug called megestrol acetate can help prevent weight loss in people with stage III stomach cancer who are about to have surgery. About 48 participants will receive either standard treatment (chemoimmunotherapy) or standard treatment plus megestrol acetate. The goal is to see if the drug helps maintain weight and appetite during treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital of Nanjing Medical Unviersity
Nanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.